Human_NP Cytomegalovirus_NP US2_NP Causes_NP Similar_JJ Effects_NNS on_IN Both_DT Major_NP Histocompatibility_NN Complex_NP Class_NP I_NP and_CC II_NP Proteins_NPS in_IN Epithelial_NP and_CC Glial_NP Cells_NP The_DT human_JJ cytomegalovirus_NN (_( HCMV_NP )_) glycoprotein_NN US2_NN specifically_RB binds_VBZ to_TO major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) class_VBP I_PP heavy_JJ chain_NN (_( HC_NP )_) and_CC class_VB II_NP proteins_NNS DRalpha_NP and_CC DMalpha_NP ,_, triggering_VBG their_PP$ degradation_NN by_IN proteasomes_NNS ._SENT Effects_NNS of_IN US2_NP on_IN class_NN II_CD proteins_NNS were_VBD originally_RB characterized_VBN in_IN HCMV-_NP or_CC adenovirus_NN vector-infected_JJ U373_NP astroglioma_NN cells_NNS ._SENT Here_RB ,_, we_PP have_VBP extended_VBN characterization_NN of_IN US2-mediated_JJ degradation_NN of_IN class_NN II_NP DRalpha_NP to_TO two_CD other_JJ cell_NN lines_NNS ,_, including_VBG biologically_RB relevant_JJ epithelial_JJ cells_NNS ._SENT Comparison_NN of_IN the_DT effects_NNS of_IN US2_NP in_IN cells_NNS expressing_VBG both_DT class_NN I_PP and_CC II_NP proteins_NNS demonstrated_VBD only_RB a_DT slight_JJ preference_NN for_IN class_NN I_NP HC_NP ._SENT Moreover_RB ,_, US2_NP caused_VBD degradation_NN of_IN DRalpha_NP and_CC DMalpha_NP when_WRB these_DT proteins_NNS were_VBD expressed_VBN by_IN transfection_NN without_IN DRbeta_NP ,_, invariant_JJ chain_NN (_( Ii_NP )_) ,_, or_CC DMbeta_NP ._SENT Therefore_RB ,_, US2_JJ binds_NNS to_TO alpha_NN chains_NNS of_IN DR_NP and_CC DM_NP and_CC triggers_VBZ endoplasmic_JJ reticulum_NN degradation_NN without_IN formation_NN of_IN class_NN II_NP DR_NP alphabeta/Ii_NP or_CC DM_NP alphabeta_NN complexes_NNS ._SENT Similar_JJ levels_NNS of_IN degradation_NN of_IN class_NN II_NP alpha_NN were_VBD observed_VBN in_IN cells_NNS expressing_VBG vastly_RB different_JJ amounts_NNS of_IN class_NN II_NP ,_, suggesting_VBG that_IN cellular_JJ factors_NNS ,_, other_JJ than_IN class_NN II_NP ,_, were_VBD limiting_VBG ._SENT We_PP concluded_VBD that_IN US2_NP has_VBZ broad_JJ effects_NNS in_IN a_DT variety_NN of_IN cells_NNS that_WDT express_VBP both_DT class_NN I_PP and_CC II_NP proteins_NNS and_CC is_VBZ relevant_JJ to_TO HCMV_NP infection_NN in_IN vivo_RB ._SENT Human_JJ cytomegalovirus_NN (_( HCMV_NP )_) is_VBZ a_DT ubiquitous_JJ beta-herpesvirus_NN that_WDT causes_VBZ lifelong_JJ infections_NNS characterized_VBN by_IN low-level_JJ persistence_NN ,_, latency_NN ,_, and_CC bouts_NNS of_IN reactivation_NN ._SENT HCMV_NP expresses_VBZ a_DT plethora_NN of_IN proteins_NNS that_WDT allow_VBP escape_NN from_IN host_NN immunity_NN ,_, and_CC these_DT likely_JJ play_NN a_DT major_JJ role_NN in_IN persistence_NN ._SENT The_DT HCMV_NP genome_NN contains_VBZ a_DT cassette_NN of_IN genes_NNS in_IN the_DT US2_NN to_TO US11_JJ region_NN that_WDT encode_VBP eight_CD homologous_JJ glycoproteins_NNS ._SENT Five_CD of_IN these_DT ,_, US2_NP ,_, US3_NP ,_, US6_NP ,_, US10_NP ,_, and_CC US11_NP ,_, inhibit_VBP the_DT major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) class_VBP I_PP pathway_NN and_CC antigen_NN presentation_NN to_TO CD8+_NP T_NN lymphocytes_NNS ._SENT We_PP have_VBP proposed_VBN that_IN these_DT and_CC other_JJ HCMV_NP immune_JJ evasion_NN strategies_NNS function_VBP during_IN a_DT specific_JJ time_NN of_IN viral_JJ life_NN cycle_NN ,_, or_CC in_IN specific_JJ cells_NNS ,_, creating_VBG a_DT window_NN of_IN opportunity_NN for_IN transient_JJ virus_NN replication_NN and_CC spread_NN (_( reviewed_VBN in_IN references_NNS ,_, ,_, and_CC )_) ._SENT HCMV_NP not_RB only_RB blocks_VBZ MHC_NP class_NN I-mediated_JJ presentation_NN of_IN viral_JJ antigens_NNS to_TO CD8+_NP T_NN cells_NNS but_CC also_RB inhibits_VBZ the_DT class_NN II_NP antigen_NN presentation_NN pathway_NN ,_, allowing_VBG the_DT virus_NN to_TO avoid_VB detection_NN by_IN CD4+_NP T_NN cells_NNS (_( reviewed_VBN in_IN references_NNS and_CC )_) ._SENT MHC_NP class_NN II_NP proteins_NNS are_VBP normally_RB expressed_VBN by_IN professional_JJ antigen-presenting_JJ cells_NNS (_( APCs_NP )_) like_IN B_NP cells_NNS ,_, macrophages_NNS ,_, and_CC dendritic_JJ cells_NNS (_( DCs_NP )_) ._SENT HCMV_NP may_MD infect_VB certain_JJ APCs_NNS ,_, especially_RB monocyte-macrophages_NNS ,_, but_CC only_RB at_IN a_DT specific_JJ stage_NN of_IN activation_NN and_CC often_RB abortively_RB or_CC inefficiently_RB (_( reviewed_VBN in_IN reference_NN )_) ._SENT HCMV_NP also_RB replicates_VBZ in_IN epithelial_JJ cells_NNS of_IN alimentary_JJ and_CC upper_JJ respiratory_JJ tracts_NNS ,_, vascular_JJ endothelial_JJ cells_NNS ,_, and_CC glial_NN cells_NNS (_( reviewed_VBN in_IN reference_NN )_) ,_, cells_NNS that_WDT express_VBP MHC_NP class_NN II_NP naturally_RB ,_, especially_RB after_IN induction_NN by_IN gamma_NN interferon_NN (_( IFN-gamma_NP )_) ._SENT HCMV_NP inhibits_VBZ IFN-gamma_NP signaling_VBG and_CC induction_NN of_IN class_NN II_CD promoters_NNS ,_, reducing_VBG the_DT inducible_JJ expression_NN of_IN class_NN II_CD genes_NNS ._SENT However_RB ,_, even_RB before_IN this_DT inhibition_NN of_IN class_NN II_NP transcription_NN ,_, HCMV_NP early_JJ glycoproteins_NNS US2_NP and_CC US3_NP inhibit_VBP class_NN II_NP antigen_NN presentation_NN by_IN destroying_VBG or_CC abolishing_VBG the_DT functions_NNS of_IN class_NN II_CD proteins_NNS ._SENT US2_NP binds_VBZ to_TO class_VB II_NP DR_NP and_CC causes_VBZ rapid_JJ and_CC efficient_JJ proteosome-mediated_JJ degradation_NN of_IN only_RB the_DT alpha_NN chain_NN of_IN the_DT class_NN II_NP DR_NP alphabeta_NN complex_NN ._SENT US2_NP also_RB causes_VBZ degradation_NN of_IN the_DT alpha_NN chain_NN of_IN DM_NP ,_, an_DT MHC_NP class_NN II_NP complex_NN required_VBN for_IN loading_NN of_IN antigenic_JJ peptides_NNS onto_IN class_NN II_NP DR_NP complexes_NNS (_( reviewed_VBN in_IN reference_NN )_) ._SENT HCMV_NP US3_NP binds_VBZ to_TO class_VB II_NP DR_NP alphabeta_NN heterodimers_NNS ,_, inhibiting_VBG binding_JJ of_IN the_DT invariant_JJ chain_NN (_( Ii_NP )_) ,_, leading_VBG to_TO intracellular_JJ mislocalization_NN and_CC reduced_VBN peptide_NN loading_NN of_IN DR_NP complexes_NNS ._SENT Our_PP$ laboratory_NN 's_POS previous_JJ characterization_NN of_IN the_DT effects_NNS of_IN US2_NP on_IN class_NN II_CD proteins_NNS involved_VBN U373_NP astroglioma_NN cells_NNS expressing_VBG the_DT human_JJ class_NN II_NP transactivator_NP (_( CIITA_NP )_) and_CC infected_VBN with_IN either_DT HCMV_NP or_CC with_IN replication-defective_JJ adenovirus_NN (_( Ad_NN )_) vectors_NNS ._SENT Recent_JJ studies_NNS involving_VBG bacterially_RB produced_VBN ,_, in_IN vitro-translated_JJ ,_, or_CC Ad-expressed_NP US2_NP lead_NN to_TO suggestions_NNS that_IN US2_NP might_MD not_RB cause_VB degradation_NN of_IN class_NN II_CD proteins_NNS in_IN vitro_NN or_CC in_IN DCs_NP ._SENT These_DT authors_NNS also_RB suggested_VBD that_IN US2_NP might_MD not_RB generally_RB affect_VB class_NN II_NP in_IN other_JJ cells_NNS and_CC that_IN effects_NNS might_MD be_VB limited_VBN to_TO U373_NP cells_NNS ,_, and_CC they_PP suggested_VBD that_IN glial_NN cells_NNS do_VBP not_RB normally_RB express_JJ class_NN II_NP ._SENT In_IN fact_NN ,_, glial_NN cells_NNS and_CC other_JJ cell_NN types_NNS that_WDT HCMV_NP infects_VBZ frequently_RB in_IN vivo_RB ,_, including_VBG epithelial_JJ and_CC endothelial_JJ cells_NNS ,_, express_JJ class_NN II_NP proteins_NNS ,_, although_IN generally_RB lower_JJR levels_NNS are_VBP produced_VBN compared_VBN with_IN DCs_NP and_CC expression_NN is_VBZ often_RB upregulated_JJ by_IN IFN-gamma_NP (_( reviewed_VBN in_IN reference_NN )_) ._SENT DCs_NNS and_CC other_JJ so-called_JJ professional_JJ APCs_NNS such_JJ as_IN monocyte-macrophages_NNS are_VBP probably_RB much_RB less_RBR relevant_JJ in_IN terms_NNS of_IN the_DT effects_NNS of_IN HCMV_NP US2_NP and_CC US3_NP ._SENT These_DT cells_NNS are_VBP poorly_RB infected_VBN by_IN HCMV_NP ,_, expression_NN of_IN HCMV_NP gene_NN products_NNS is_VBZ often_RB relatively_RB low_JJ ,_, and_CC class_NN II_NP proteins_NNS are_VBP expressed_VBN at_IN high_JJ levels_NNS ._SENT Rehm_NP et_FW al._FW found_VBN insufficient_JJ levels_NNS of_IN US2_NP were_VBD expressed_VBN by_IN using_VBG Ad_NN vectors_NNS ,_, so_RB that_IN neither_DT class_NN I_PP or_CC class_VB II_NP proteins_NNS were_VBD substantially_RB affected_VBN ._SENT It_PP is_VBZ not_RB clear_JJ whether_IN US2_NP might_MD have_VB caused_VBN degradation_NN of_IN class_NN II_NP in_IN DCs_NP had_VBD enough_NN US2_NN been_VBN delivered_VBN ._SENT To_TO characterize_VB whether_IN US2_NP has_VBZ general_JJ effects_NNS on_IN MHC_NP class_NN II_CD proteins_NNS in_IN a_DT variety_NN of_IN cells_NNS ,_, we_PP characterized_VBD US2-mediated_JJ degradation_NN of_IN class_NN I_PP and_CC II_NP proteins_NNS in_IN several_JJ different_JJ cell_NN lines_NNS ,_, including_VBG two_CD human_JJ epithelial_JJ cell_NN lines_NNS ._SENT US2_NP showed_VBD only_RB a_DT slight_JJ preference_NN for_IN class_NN I_PP compared_VBN with_IN class_NN II_CD proteins_NNS ._SENT US2_NP triggered_VBD efficient_JJ degradation_NN of_IN the_DT class_NN II_NP DRalpha_NP and_CC DMalpha_NP proteins_NNS when_WRB these_DT were_VBD expressed_VBN without_IN the_DT DRbeta_NP or_CC DMbeta_NP chains_NNS ._SENT Cells_NNS with_IN substantial_JJ differences_NNS in_IN levels_NNS of_IN class_NN II_NP proteins_NNS displayed_VBD similar_JJ degradation_NN at_IN any_DT given_VBN level_NN of_IN US2_NP ,_, supporting_VBG the_DT hypothesis_NN that_IN cellular_JJ factors_NNS apart_RB from_IN MHC_NP proteins_NNS are_VBP limiting_VBG in_IN US2-induced_JJ endoplasmic_JJ reticulum_NN (_( ER_JJ )_) degradation_NN ._SENT Cells_NNS ._SENT |_SYM All_DT cell_NN lines_NNS were_VBD propagated_VBN in_IN media_NNS supplemented_VBN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( HyClone_NP ,_, Logan_NP ,_, Utah_NP )_) ,_, 2_CD mM_NP l-glutamine_NN ,_, 100_CD U_NN of_IN penicillin/ml_NN ,_, and_CC 100_CD mug_NN of_IN streptomycin_NN (_( Biowhittaker_NP ,_, Walkersville_NP ,_, Md.)/ml_NP ,_, unless_IN otherwise_RB stated_VBN ._SENT HeLa_NP ,_, U373-MG_NP (_( American_NP Type_NP Culture_NP Collection_NP ,_, Manassas_NP ,_, Va._NP )_) ,_, and_CC 293_CD (_( Microbix_NP ,_, Toronto_NP ,_, Ontario_NP ,_, Canada_NP )_) cells_NNS were_VBD propagated_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( DMEM_NP ;_: Mediatec_NP ,_, Herndon_NP ,_, Va._NP )_) ._SENT His16_NP and_CC Neo6_NP cells_NNS were_VBD derived_VBN by_IN stable_JJ transfection_NN of_IN the_DT human_JJ astroglioma_NN cells_NNS U373-MG_NN with_IN the_DT human_JJ class_NN II_NP transactivator_NN CIITA_NP and_CC pSV2His_NP or_CC pSV2Neo_NP ,_, respectively_RB ._SENT His16_NN cells_NNS were_VBD propagated_VBN in_IN DMEM_NP lacking_JJ histidine_NN (_( University_NP of_IN California_NP San_NP Francisco_NP Cell_NP Culture_NP Facility_NP ,_, San_NP Francisco_NP ,_, Calif._NP )_) and_CC supplemented_VBN with_IN 0.5_CD mM_NP histidinol_NP (_( Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ._SENT Neo6_NP cells_NNS were_VBD grown_VBN in_IN DMEM_NP supplemented_VBD with_IN 200_CD mug_NN of_IN G418_NP sulfate_NN (GIBCO)/ml_NN ._SENT HeLa-CIITA_NP cells_NNS were_VBD a_DT gift_NN from_IN Philip_NP Benaroch_NP ,_, Institut_NP Curie_NP ,_, Paris_NP ,_, France_NP ,_, and_CC were_VBD grown_VBN in_IN DMEM_NP supplemented_VBD with_IN 300_CD mug_NN of_IN hygromycin_NN (Sigma)/ml_NN ._SENT 2E12_JJ cells_NNS ,_, which_WDT are_VBP AGS_NP human_JJ gastric_JJ carcinoma_NN cells_NNS stably_RB transfected_VBN with_IN CIITA_NP ,_, were_VBD a_DT gift_NN from_IN Lindsey_NP Hutt-Fletcher_NP ,_, University_NP of_IN Missouri_NP ,_, Kansas_NP City_NP ,_, and_CC were_VBD propagated_VBN in_IN Ham_NP 's_POS F12_NP medium_NN supplemented_VBD with_IN 0.4_CD mug_NN of_IN puromycin/ml_NN ._SENT Recombinant_JJ Ad_NN 's_POS ._SENT |_SYM Replication-defective_NP (_( E1-_NP )_) Ad_NN vectors_NNS expressing_VBG HCMV_NP US2_NP ,_, US3_NP ,_, US7_JJ ,_, and_CC US11_NP have_VBP been_VBN described_VBN previously_RB ._SENT Briefly_RB ,_, the_DT relevant_JJ genes_NNS were_VBD amplified_VBN by_IN PCR_NP from_IN HCMV_NP strain_NN AD169_NP and_CC inserted_VBN into_IN plasmid_NP pDeltaE1sp1Btet_NN ._SENT 293_CD cells_NNS were_VBD cotransfected_VBN with_IN pJM17_JJ ,_, a_DT plasmid_NN containing_VBG the_DT Ad_NN type_NN 5_CD genome_NN ,_, and_CC each_DT of_IN the_DT above_JJ plasmids_NNS ._SENT Recombinant_JJ Ad_NN vectors_NNS were_VBD screened_VBN by_IN PCR_NP ._SENT The_DT resulting_VBG viruses_NNS ,_, AdtetUS2_NP ,_, AdtetUS3_NP ,_, AdtetUS7_JJ ,_, and_CC AdtetUS11_NP ,_, were_VBD plaque_NN purified_VBN twice_RB to_TO eliminate_VB wild-type_NN virus_NN ._SENT For_IN expression_NN of_IN the_DT glycoproteins_NNS ,_, cells_NNS were_VBD coinfected_VBN with_IN these_DT viruses_NNS and_CC a_DT second_JJ virus_NN ,_, Adtet-trans_NP ,_, using_VBG 20_CD %_NN of_IN the_DT amount_NN of_IN AdtetUS_NP virus_NN ._SENT Infections_NNS were_VBD carried_VBN out_RP in_IN the_DT absence_NN of_IN tetracycline_NN ,_, which_WDT represses_VBZ the_DT tet-trans_NNS promoter_NN ._SENT AdBHG10T7Rbetagal_NP (_( Adbetagal_NP [_SYM 49_CD ]_SYM )_) was_VBD obtained_VBN from_IN Frank_NP Graham_NP ,_, McMaster_NP University_NP ,_, Hamilton_NP ,_, Ontario_NP ,_, Canada_NP ._SENT Adbetagal_NP was_VBD constructed_VBN by_IN recombination_NN between_IN a_DT shuttle_NN plasmid_NN containing_VBG the_DT T7_JJ promoter_NN ,_, beta-galactosidase_NN gene_NN ,_, and_CC simian_JJ virus_NN 40_CD poly(A)_NN sequences_NNS and_CC the_DT circular_JJ Ad5_NP genomic_JJ plasmid_NN pBHG10_NN ,_, as_RB described_VBN elsewhere_RB ._SENT Other_JJ recombinant_JJ Ad_NN 's_POS (_( E1-_NP ,_, E3-_NP )_) encoding_VBG US11_NP and_CC US2_NP were_VBD obtained_VBN from_IN Armin_NP Rehm_NP ,_, Max_NP Delbruck_NP Center_NP for_IN Molecular_NP Medicine_NP ,_, Berlin_NP ,_, Germany_NP ._SENT Briefly_RB ,_, the_DT genes_NNS were_VBD coupled_VBN to_TO the_DT HCMV_NP immediate-early_JJ promoter_NN and_CC bovine_JJ growth_NN hormone_NN poly(A)_NN signal_NN in_IN a_DT shuttle_NN vector_NN ._SENT Recombination_NN with_IN the_DT viral_JJ vector_NN was_VBD performed_VBN in_IN Escherichia_NP coli_NNS for_IN US11_NP and_CC in_IN 293_CD cells_NNS for_IN US2_NP ._SENT We_PP refer_VBP to_TO these_DT viruses_NNS as_IN AdUS2_NP and_CC AdUS11_NP ,_, as_RB opposed_VBN to_TO our_PP$ tetracycline_NN transactivator-regulated_JJ AdtetUS_NP viruses_NNS ._SENT All_DT Ad_NN vectors_NNS were_VBD propagated_VBN and_CC titers_NNS were_VBD determined_VBN on_IN 293_CD cells_NNS as_RB described_VBD previously_RB ._SENT Plasmids_NNS and_CC antibodies_NNS ._SENT |_SYM Eukaryotic_JJ expression_NN constructs_NNS encoding_VBG human_JJ leukocyte_NN antigen_NN (HLA)-DRalpha_NP or_CC HLA-DRbeta_NP were_VBD gifts_NNS from_IN Elizabeth_NP Mellins_NP ,_, Stanford_NP University_NP ,_, Palo_NP Alto_NP ,_, Calif._NP Rabbit_NP antiserum_NN to_TO the_DT N-terminal_JJ peptide_NN of_IN US2_NP has_VBZ been_VBN described_VBN previously_RB ._SENT The_DT monoclonal_NN antibody_NN (_( MAb_NP )_) HC10_NP ,_, specific_JJ for_IN class_NN I_PP heavy_JJ chain_NN (_( HC_NP )_) ,_, was_VBD obtained_VBN from_IN Hidde_NP Ploegh_NP ,_, Harvard_NP Medical_NP School_NP ,_, Boston_NP ,_, Mass._NP MAb_NP 's_VBZ to_TO HLA-DRalpha_NP (_( DA6.147_NP )_) and_CC HLA-DRbeta_NP (_( HB10A_NP )_) were_VBD gifts_NNS from_IN Peter_NP Cresswell_NP ,_, Yale_NP University_NP ,_, New_NP Haven_NP ,_, Conn._NP The_NP MAb_NP to_TO HLA-DMalpha_NP was_VBD a_DT gift_NN from_IN John_NP Trowsdale_NP ,_, Cambridge_NP University_NP ,_, Cambridge_NP ,_, United_NP Kingdom_NP ._SENT The_DT MAb_NP (_( B3/25_NP )_) to_TO human_JJ transferrin_NN receptor_NN was_VBD obtained_VBN from_IN Roche_NP Molecular_NP Corp._NP ,_, Indianapolis_NP ,_, Ind._NP Transfections_NNS ._SENT |_SYM For_IN transient_JJ expression_NN of_IN class_NN II_CD proteins_NNS ,_, HeLa_NP cells_NNS were_VBD transfected_VBN with_IN plasmid_NP DNA_NP containing_VBG relevant_JJ genes_NNS by_IN using_VBG the_DT Geneporter_NP 2_CD transfection_NN reagent_NN ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS (_( Gene_NP Therapy_NP Systems_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ._SENT Briefly_RB ,_, 106_CD cells_NNS were_VBD seeded_VBN into_IN 60-mm_NP Falcon_NP tissue_NN culture_NN dishes_NNS (_( Becton_NP Dickinson_NP ,_, Franklin_NP Lakes_NP ,_, N.J._NP )_) and_CC transfected_VBD the_DT next_JJ day_NN with_IN 4_CD to_TO 6_CD mug_NN of_IN DNA_NN in_IN serum-free_JJ Opti-MEM_NP (_( GIBCO_NP )_) ._SENT For_IN expression_NN of_IN HCMV_NP glycoproteins_NNS ,_, the_DT transfected_JJ cells_NNS were_VBD infected_VBN with_IN Ad_NP vectors_NNS 48_CD to_TO 60_CD h_NN posttransfection_NN after_IN the_DT cells_NNS had_VBD reached_VBN 4_CD x_SYM 106_CD cells/dish_NN ._SENT Metabolic_JJ labeling_VBG of_IN cells_NNS and_CC immunoprecipitation_NN of_IN proteins_NNS ._SENT |_SYM Cells_NP were_VBD radiolabeled_VBN after_IN 18_CD to_TO 20_CD h_NN of_IN infection_NN with_IN recombinant_JJ Ad_NN vectors_NNS ._SENT In_IN general_JJ ,_, cells_NNS were_VBD plated_VBN in_IN 150-mm_NP Nunclon_NP tissue_NN culture_NN dishes_NNS (_( Nalge_NP Nunc_NP International_NP ,_, Rochester_NP ,_, N.Y._NP )_) at_IN a_DT density_NN of_IN 6_CD x_NN 106_CD (_( His16_NN ,_, Neo6_NP ,_, or_CC 2E12_JJ )_) or_CC 15_CD x_NN 106_CD (_( HeLa-CIITA_NP )_) cells_NNS per_IN dish_NN and_CC infected_VBD the_DT next_JJ day_NN ._SENT Infected_JJ or_CC control_NN cells_NNS were_VBD washed_VBN in_IN DMEM_NP lacking_JJ methionine_NN and_CC cysteine_NN (_( GIBCO_NP )_) and_CC then_RB incubated_VBN for_IN 1_CD h_NN in_IN the_DT same_JJ medium_NN containing_VBG 1_CD %_NN dialyzed_VBD fetal_JJ bovine_JJ serum_NN (_( starvation_NN medium_NN )_) ._SENT Cells_NNS were_VBD labeled_VBN for_IN various_JJ time_NN periods_NNS in_IN starvation_NN medium_NN supplemented_VBN with_IN [_SYM 35S]methionine-cysteine_JJ (_( Promix_NP ;_: Amersham_NP Pharmacia_NP Biotech_NP ,_, Piscataway_NP ,_, N.J._NP )_) ._SENT For_IN longer_JJR periods_NNS ,_, e.g._FW ,_, 3_CD h_NN ,_, adherent_JJ cells_NNS were_VBD labeled_VBN in_IN tissue_NN culture_NN dishes_NNS with_IN 50_CD to_TO 100_CD muCi_NNS of_IN [_SYM 35S]methionine-cysteine/ml_JJ ._SENT For_IN short_JJ pulse_NN labels_NNS ,_, cells_NNS were_VBD trypsinized_VBN ,_, washed_VBN twice_RB in_IN DMEM_NP lacking_JJ methionine_NN and_CC cysteine_NN ,_, and_CC labeled_VBN in_IN suspension_NN with_IN 500_CD muCi_NNS of_IN [_SYM 35S]methionine-cysteine/ml_JJ ._SENT To_TO chase_VB the_DT label_NN ,_, cells_NNS were_VBD incubated_VBN in_IN medium_NN containing_VBG 10-fold_JJ excess_JJ methionine_NN and_CC cysteine_NN ._SENT The_DT cells_NNS were_VBD then_RB washed_VBN with_IN cold_JJ phosphate-buffered_JJ saline_NN ,_, and_CC cell_NN extracts_VBZ were_VBD made_VBN using_VBG Nonidet_NP P-40-deoxycholate_NP (_( NP-40-DOC_NP )_) lysis_NN buffer_NN (_( 50_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.5_CD ]_SYM ,_, 100_CD mM_NP NaCl_NP ,_, 1_CD %_NN NP-40_NP ,_, 0.5_CD %_NN DOC_NP ,_, 1_CD mg_NN of_IN bovine_JJ serum_NN albumin_NN [_SYM BSA]/ml_NP ,_, and_CC a_DT cocktail_NN of_IN protease_NN inhibitors_NNS )_) ._SENT For_IN denaturation_NN of_IN protein_NN complexes_NNS ,_, cell_NN extracts_VBZ were_VBD made_VBN in_IN small_JJ volumes_NNS with_IN sodium_NN dodecyl_NN sulfate_NN (_( SDS_NP )_) lysis_NN buffer_NN comprised_VBN of_IN 50_CD mM_NP Tris_NP (_( pH_NN 7.4_CD )_) ,_, 100_CD mM_NP NaCl_NP (_( Tris-saline_NP )_) ,_, 1_CD %_NN SDS_NP ,_, 1_CD mg_NN of_IN BSA/ml_NP ,_, and_CC a_DT cocktail_NN of_IN protease_NN inhibitors_NNS and_CC boiled_VBD for_IN 10_CD min_NN ._SENT SDS_NP was_VBD then_RB diluted_VBN 10-fold_NN by_IN addition_NN of_IN Tris-saline_NP containing_VBG 1_CD %_NN Triton_NP X-100_NP ,_, 1_CD mg_NN of_IN BSA/ml_NP ,_, and_CC a_DT cocktail_NN of_IN protease_NN inhibitors_NNS ._SENT Proteins_NNS of_IN interest_NN were_VBD immunoprecipitated_VBN by_IN incubating_VBG cell_NN extracts_VBZ with_IN the_DT appropriate_JJ antibody_NN for_IN 2_CD h_NN and_CC subsequently_RB with_IN protein-A_NN agarose_NN beads_NNS for_IN 2_CD h_NN ,_, as_RB described_VBN previously_RB ._SENT Electrophoresis_NN and_CC autoradiography_NN ._SENT |_SYM Immunoprecipitated_NP proteins_NNS were_VBD eluted_VBN by_IN boiling_VBG in_IN 2_CD %_NN SDS_NP and_CC then_RB subjected_VBN to_TO electrophoresis_NN using_VBG 10_CD to_TO 12_CD %_NN polyacrylamide_NN gels_NNS ,_, as_RB described_VBN elsewhere_RB ._SENT The_DT gels_NNS were_VBD fixed_VBN in_IN 30_CD %_NN acetic_JJ acid_NN and_CC 10_CD %_NN methanol_NN and_CC treated_VBN with_IN Enlightning_NP (_( New_NP England_NP Nuclear_NP ,_, Beverly_NP ,_, Mass._NP )_) ,_, dried_VBD ,_, and_CC exposed_VBN to_TO X-ray_NN film_NN (_( Eastman_NP Kodak_NP Company_NP ,_, Rochester_NP ,_, N.Y._NP )_) or_CC PhosphorImager_NP screens_NNS (_( Molecular_NP Dynamics_NP ,_, Sunnyvale_NP ,_, Calif._NP )_) ._SENT Protein_NN bands_NNS were_VBD quantified_VBN by_IN using_VBG the_DT PhosphorImager_NP BAS2500_NP system_NN (_( Molecular_NP Dynamics_NPS )_) ._SENT Class_NP II_NP complexes_NNS are_VBP lost_VBN in_IN a_DT dose-dependent_JJ manner_NN in_IN US2-expressing_NP epithelial_JJ and_CC glial_NN cells_NNS ._SENT |_SYM His16_NN cells_NNS are_VBP U373_JJ cells_NNS transfected_VBN with_IN CIITA_NP and_CC express_JJ substantial_JJ quantities_NNS of_IN class_NN II_NP alpha_NN ,_, beta_NN ,_, and_CC Ii_NP ,_, and_CC they_PP efficiently_RB present_VBP antigens_NNS to_TO CD4+_NP T_NN cells_NNS ._SENT To_TO extend_VB our_PP$ observations_NNS beyond_IN His16_JJ cells_NNS ,_, we_PP obtained_VBD HeLa_NP cervical_JJ carcinoma_NN and_CC AGS_NP gastric_JJ carcinoma_NN cells_NNS that_WDT had_VBD both_DT been_VBN stably_RB transfected_VBN with_IN CIITA_NP ._SENT Initially_RB ,_, the_DT levels_NNS of_IN expression_NN of_IN class_NN II_CD proteins_NNS were_VBD examined_VBN in_IN a_DT pulse-chase_NN labeling_VBG format_NN ._SENT His16_NN ,_, HeLa-CIITA_NP ,_, and_CC 2E12_JJ (_( AGS-CIITA_NP )_) cells_NNS were_VBD labeled_VBN in_IN suspension_NN for_IN 2_CD ,_, 4_CD ,_, or_CC 8_CD min_NN ,_, and_CC the_DT label_NN was_VBD chased_VBN for_IN 0_CD or_CC 20_CD min_NN ._SENT All_DT three_CD cell_NN types_NNS expressed_VBD class_NN II_CD proteins_NNS ,_, although_IN at_IN lower_JJR levels_NNS in_IN the_DT HeLa-CIITA_NP cells_NNS ._SENT In_IN longer_RBR labeling_VBG periods_NNS and_CC in_IN chase_JJ samples_NNS ,_, the_DT beta_JJ chain_NN was_VBD coprecipitated_VBN with_IN alpha_NN chains_NNS by_IN MAb_NP DA6.147_NP ,_, an_DT antibody_NN that_WDT recognizes_VBZ the_DT cytoplasmic_JJ domain_NN of_IN the_DT class_NN II_NP alpha_NN chain_NN but_CC that_WDT can_MD also_RB precipitate_VB alphabeta_NN complexes_NNS ._SENT With_IN all_PDT the_DT cell_NN lines_NNS ,_, the_DT detection_NN of_IN class_NN II_CD proteins_NNS increased_VBN with_IN longer_JJR periods_NNS of_IN labeling_VBG or_CC chase_JJ ,_, due_JJ in_IN part_NN to_TO acquisition_NN of_IN antibody_NN epitopes_NNS ._SENT Normalization_NN of_IN class_NN II_NP expression_NN to_TO cell_NN number_NN indicated_VBD that_IN HeLa-CIITA_NP and_CC 2E12_JJ cells_NNS express_VBP ~10_JJ %_NN and_CC ~60_NN %_NN of_IN class_NN II_CD proteins_NNS compared_VBN to_TO His16_JJ cells_NNS ._SENT The_DT respective_JJ parental_JJ cell_NN lines_NNS expressed_VBD much_RB lower_JJR levels_NNS of_IN class_NN II_CD proteins_NNS (_( data_NNS not_RB shown_VBN )_) ,_, although_IN it_PP should_MD be_VB noted_VBN that_IN U373_NP cells_NNS (_( without_IN CIITA_NP transfection_NN )_) less_CC efficiently_RB present_JJ antigens_NNS to_TO CD4+_NP T_NN cells_NNS ._SENT Replication-defective_JJ Ad_NN vectors_NNS have_VBP been_VBN used_VBN to_TO study_VB the_DT biochemical_JJ effects_NNS of_IN HCMV_NP proteins_NNS in_IN U373_JJ cells_NNS because_IN infection_NN of_IN U373_JJ cells_NNS with_IN HCMV_NP is_VBZ frequently_RB inefficient_JJ ._SENT Here_RB ,_, we_PP have_VBP used_VBN an_DT Ad_NN vector_NN to_TO deliver_VB US2_NP into_IN HeLa-CIITA_NP and_CC 2E12_JJ epithelial_JJ cells_NNS ,_, as_RB well_RB as_IN His16_JJ glial_NN cells_NNS ,_, and_CC in_IN every_DT case_NN class_NN II_NP was_VBD lost_VBN in_IN a_DT US2_JJ dose-dependent_NN manner_NN ._SENT The_DT control_NN Ad_NN vector_NN ,_, Adtet-trans_NP ,_, slightly_RB increased_VBD the_DT amount_NN of_IN class_NN II_NP in_IN a_DT dose-dependent_JJ fashion_NN (_( data_NNS not_RB shown_VBN )_) ,_, similar_JJ to_TO previous_JJ observations_NNS from_IN our_PP$ laboratory_NN ._SENT Since_IN it_PP has_VBZ been_VBN suggested_VBN that_IN the_DT effects_NNS of_IN US2_NP were_VBD related_VBN to_TO overexpression_NN of_IN a_DT glycoprotein_NN that_IN accumulated_VBN in_IN the_DT ER_NN or_CC to_TO consequences_NNS of_IN CIITA_NP expression_NN ,_, we_PP compared_VBD the_DT effects_NNS of_IN US2_NP to_TO HCMV_NP US3_NP and_CC US7_JJ ,_, homologous_JJ glycoproteins_NNS that_WDT do_VBP not_RB cause_VB degradation_NN of_IN MHC_NP proteins_NNS ._SENT There_EX was_VBD no_DT obvious_JJ effect_NN of_IN expressing_VBG US3_JJ or_CC US7_JJ in_IN either_DT His16_NN or_CC HeLa-CIITA_NP cells_NNS ._SENT Similar_JJ results_NNS were_VBD also_RB obtained_VBN with_IN Neo6_NP and_CC 2E12_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Therefore_RB ,_, US2_NP causes_VBZ degradation_NN of_IN class_NN II_NP alpha_NN with_IN similar_JJ doses_NNS in_IN several_JJ cell_NN types_NNS ._SENT Degradation_NN of_IN class_NN II_NP alpha_NN chains_NNS in_IN cells_NNS expressing_VBG only_JJ DRalpha_NP or_CC DMalpha_NP ._SENT |_SYM US2_NP triggers_NNS degradation_NN of_IN the_DT class_NN II_NP alpha_NN chain_NN shortly_RB after_IN its_PP$ synthesis_NN while_IN not_RB affecting_VBG beta_NN and_CC Ii_NP chains_NNS ._SENT However_RB ,_, it_PP is_VBZ not_RB clear_JJ whether_IN US2_JJ binds_NNS preferentially_RB to_TO alphabeta_NN or_CC alphabeta/Ii_NN complexes_NNS or_CC whether_IN beta_NN or_CC Ii_NP are_VBP required_VBN for_IN degradation_NN ._SENT To_TO analyze_VB this_DT further_JJR ,_, we_PP transiently_RB transfected_VBD HeLa_NP cells_NNS with_IN plasmids_NNS encoding_VBG just_RB DRalpha_NP ,_, DRbeta_NP ,_, or_CC DMalpha_NP chains_NNS and_CC then_RB delivered_VBN various_JJ doses_NNS of_IN US2_NP ._SENT When_WRB expressed_VBN alone_RB in_IN HeLa_NP cells_NNS ,_, DRalpha_NP was_VBD degraded_VBN in_IN a_DT dose-dependent_JJ manner_NN but_CC DRbeta_NP was_VBD not_RB affected_VBN by_IN US2_JJ expression_NN ._SENT When_WRB both_DT alpha_NN and_CC beta_NN were_VBD cotransfected_VBN into_IN HeLa_NP cells_NNS (_( HeLa/DRalpha/DRbeta_NP )_) ,_, both_CC the_DT alpha_NN and_CC beta_NN chains_NNS disappeared_VBD because_IN an_DT antibody_NN specific_JJ to_TO the_DT alpha_NN chain_NN was_VBD used_VBN and_CC the_DT alpha_NN chain_NN was_VBD lost_VBN ._SENT US2_NP also_RB caused_VBD degradation_NN of_IN DMalpha_NP when_WRB DMalpha_NP was_VBD expressed_VBN without_IN DMbeta_NP in_IN HeLa_NP cells_NNS (_( Fig._NN ,_, lower_JJR panel_NN )_) ._SENT Therefore_RB ,_, US2_NP can_MD bind_VB to_TO and_CC promote_VB degradation_NN of_IN DRalpha_NP and_CC DMalpha_NP without_IN other_JJ components_NNS of_IN these_DT class_NN II_CD complexes_NNS ._SENT Evidence_NN for_IN a_DT limiting_VBG cellular_JJ factor_NN ._SENT |_SYM Previous_JJ studies_NNS from_IN our_PP$ laboratory_NN ,_, involving_VBG mutant_JJ forms_NNS of_IN US2_NP ,_, demonstrated_VBD that_IN binding_VBG of_IN US2_NP to_TO MHC_NP class_NN I_PP and_CC II_NP proteins_NNS was_VBD not_RB sufficient_JJ for_IN their_PP$ degradation_NN ._SENT This_DT and_CC other_JJ lines_NNS of_IN research_NN have_VBP suggested_VBN that_IN cellular_JJ factors_NNS or_CC events_NNS beyond_IN binding_VBG of_IN US2_NP to_TO MHC_NP proteins_NNS are_VBP required_VBN for_IN the_DT degradation_NN process_NN ._SENT This_DT is_VBZ an_DT important_JJ area_NN of_IN investigation_NN because_IN US2-_NP and_CC US11-mediated_JJ degradation_NN of_IN MHC_NP proteins_NNS is_VBZ a_DT model_NN for_IN ER_JJ degradation_NN in_IN mammalian_JJ cells_NNS ._SENT His16_JJ and_CC 2E12_JJ cells_NNS expressed_VBD substantially_RB higher_JJR levels_NNS of_IN class_NN II_CD proteins_NNS than_IN HeLa_NP cells_NNS transfected_VBN with_IN the_DT DRalpha_NP gene_NN ._SENT Therefore_RB ,_, we_PP reasoned_VBD that_IN US2_NP might_MD cause_VB much_RB more_RBR rapid_JJ degradation_NN in_IN transfected_JJ HeLa_NP cells_NNS ,_, unless_IN some_DT cellular_JJ factor_NN was_VBD limiting_VBG ._SENT First_RB ,_, to_TO quantify_VB the_DT levels_NNS of_IN expression_NN of_IN DRalpha_NP in_IN His16_JJ cells_NNS and_CC transiently_RB transfected_JJ HeLa_NP cells_NNS ,_, cells_NNS were_VBD labeled_VBN for_IN 3_CD h_NN and_CC DRalpha_NP was_VBD immunoprecipitated_VBN using_VBG the_DT alpha-specific_JJ antibody_NN DA6.147_JJ ._SENT In_IN the_DT left_VBN panel_NN of_IN Fig._NN ,_, class_NN II_NP alpha/beta/Ii_NP complexes_NNS were_VBD precipitated_VBN using_VBG MAb_NP DA6.147_NP from_IN His16_JJ cell_NN extracts_VBZ made_VBN using_VBG NP-40-DOC_NP lysis_NN buffer_NN ._SENT Under_IN these_DT conditions_NNS ,_, the_DT alpha_NN and_CC Ii_NP chain_NN bands_NNS form_VBP a_DT tight_JJ doublet_NN ._SENT In_IN the_DT middle_JJ lane_NN ,_, class_NN II_CD complexes_NNS were_VBD first_RB denatured_VBN with_IN SDS_NP to_TO separate_VB Ii_NP and_CC alpha_NN chains_NNS and_CC then_RB immunoprecipitated_JJ with_IN MAb_NP DA6.147_NP ._SENT Clearly_RB ,_, DA6.147_JJ much_JJ less_CC efficiently_RB precipitated_VBD denatured_VBN DRalpha_NP under_IN these_DT conditions_NNS ,_, but_CC the_DT band_NN indicates_VBZ the_DT position_NN of_IN the_DT alpha_NN chain_NN in_IN this_DT gel_NN ._SENT In_IN the_DT right_JJ lane_NN ,_, DRalpha_NP was_VBD precipitated_VBN from_IN transfected_JJ HeLa_NP extracts_VBZ made_VBN using_VBG NP-40-DOC_NP buffer_NN (_( there_EX is_VBZ no_DT beta_NN or_CC Ii_NP in_IN these_DT cells_NNS )_) ._SENT To_TO compare_VB the_DT amount_NN of_IN alpha_NN chain_NN in_IN the_DT left_JJ and_CC right_JJ lanes_NNS ,_, we_PP used_VBD a_DT PhosphorImager_NP to_TO quantify_VB the_DT entire_JJ alpha/Ii_NN band_NN from_IN His16_JJ cells_NNS and_CC then_RB calculated_VBN the_DT contribution_NN of_IN the_DT alpha_NN chain_NN to_TO the_DT band_NN intensity_NN ,_, based_VBN on_IN the_DT relative_JJ quantities_NNS of_IN methionine_NN and_CC cysteine_NN ._SENT This_DT difference_NN ,_, combined_VBN with_IN the_DT fact_NN that_IN fourfold_RB more_JJR HeLa-DRalpha_NP cells_NNS were_VBD used_VBN ,_, established_VBD that_IN His16_NN cells_NNS expressed_VBD 20-_CD to_TO 40-fold_NN more_JJR class_NN II_NP DRalpha_NP than_IN was_VBD the_DT case_NN in_IN transfected_JJ HeLa_NP cells_NNS ._SENT In_IN Fig._NN we_PP established_VBD that_IN 2E12_JJ cells_NNS express_VBP approximately_RB 60_CD %_NN the_DT class_NN II_NP DRalpha_NP that_WDT is_VBZ expressed_VBN in_IN His16_JJ cells_NNS ._SENT Different_JJ doses_NNS of_IN US2_NP were_VBD delivered_VBN into_IN 2E12_JJ ,_, His16_JJ ,_, or_CC HeLa_NP cells_NNS transfected_VBN with_IN DRalpha_NP or_CC DRbeta_NP ._SENT The_DT loss_NN of_IN DRalpha_NP was_VBD similar_JJ in_IN the_DT three_CD different_JJ cells_NNS ,_, even_RB though_IN there_EX were_VBD 10-_CD to_TO 40-fold_NN more_JJR class_NN II_CD proteins_NNS expressed_VBN in_IN 2E12_JJ and_CC His16_JJ cells_NNS ._SENT No_DT loss_NN of_IN DRbeta_NP was_VBD observed_VBN ._SENT Expression_NN of_IN US2_NP was_VBD very_RB similar_JJ in_IN His16_NN and_CC transfected_JJ HeLa_NP cells_NNS at_IN any_DT dose_NN of_IN AdtetUS2_NP ,_, and_CC similar_JJ levels_NNS of_IN US2_NP were_VBD observed_VBN in_IN 2E12_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Further_RBR ,_, in_IN His16_NN cells_NNS and_CC HeLa_NP cells_NNS transfected_VBN with_IN the_DT DMalpha_NP gene_NN ,_, degradation_NN of_IN class_NN II_NP DMalpha_NP was_VBD similar_JJ or_CC identical_JJ at_IN any_DT given_VBN dose_NN of_IN US2_NP ._SENT Thus_RB ,_, degradation_NN of_IN both_DT DRalpha_NP and_CC DMalpha_NP occurred_VBD with_IN a_DT similar_JJ US2_JJ dose_NN response_NN ,_, even_RB though_IN substantially_RB different_JJ amounts_NNS of_IN the_DT MHC_NP class_NN II_NP proteins_NNS were_VBD present_JJ in_IN cells_NNS ._SENT This_DT supports_VBZ the_DT existence_NN of_IN cellular_JJ factors_NNS other_JJ than_IN MHC_NP proteins_NNS and_CC US2_NP that_WDT are_VBP involved_VBN and_CC limiting_VBG in_IN US2-induced_JJ ER_JJ degradation_NN of_IN MHC_NP proteins_NNS ._SENT Relative_JJ effects_NNS of_IN US2_NP on_IN class_NN I_PP HC_NP versus_IN class_NN II_NP alpha_NN chain_NN ._SENT |_SYM Based_VBN on_IN in_IN vitro_NN experiments_NNS involving_VBG recombinant_JJ forms_NNS of_IN US2_NP ,_, it_PP was_VBD suggested_VBN that_IN US2_NP only_RB affects_VBZ MHC_NP class_NN I_NP HC_NP and_CC has_VBZ little_RB or_CC no_DT effect_NN on_IN class_NN II_NP alpha_NN ._SENT In_IN mammalian_JJ cells_NNS ,_, however_RB ,_, our_PP$ group_NN has_VBZ found_VBN that_IN US2_NP affects_VBZ both_DT proteins_NNS ._SENT The_DT relative_JJ effects_NNS of_IN US2_NP on_IN MHC_NP class_NN I_PP and_CC II_NP proteins_NNS have_VBP not_RB been_VBN compared_VBN in_IN cells_NNS that_WDT express_VBP both_DT and_CC where_WRB different_JJ doses_NNS of_IN US2_NP could_MD be_VB delivered_VBN ._SENT His16_NN cells_NNS and_CC Neo6_JJ cells_NNS ,_, a_DT second_JJ CIITA-transfected_NP U373_NP cell_NN line_NN that_WDT expresses_VBZ approximately_RB half_PDT the_DT class_NN II_NP expressed_VBD in_IN His16_JJ cells_NNS ,_, were_VBD analyzed_VBN ._SENT When_WRB these_DT cells_NNS were_VBD infected_VBN with_IN low_JJ to_TO intermediate_JJ doses_NNS of_IN AdtetUS2_NP (_( 10_CD to_TO 40_CD PFU/cell_NN )_) ,_, more_JJR class_NN I_NP HC_NP was_VBD degraded_VBN than_IN class_NN II_NP DRalpha_NP in_IN both_DT His16_NN and_CC Neo6_JJ cells_NNS ._SENT However_RB ,_, the_DT preference_NN for_IN HC_NP was_VBD only_RB 1.5-_CD to_TO 2-fold_NN greater_JJR than_IN that_IN for_IN class_NN II_NP alpha_NN ._SENT At_IN higher_JJR doses_NNS of_IN US2_NP (_( 80_NP PFU/cell_NP )_) ,_, both_CC proteins_NNS were_VBD efficiently_RB degraded_VBN ._SENT Comparison_NN of_IN Ad_NN vectors_NNS expressing_VBG US2_NP ._SENT |_SYM The_DT report_NN of_IN Rehm_NP et_FW al._FW suggested_VBD that_IN an_DT Ad_NN vector_NN expressing_VBG US2_NP did_VBD not_RB affect_VB the_DT stability_NN of_IN class_NN II_NP DR_NP proteins_NNS in_IN DCs_NP ._SENT In_IN preliminary_JJ experiments_NNS ,_, we_PP were_VBD unable_JJ to_TO substantially_RB express_VB US2_NP or_CC US3_NP by_IN using_VBG Ad_NN vectors_NNS in_IN monocyte-macrophages_NNS or_CC DCs_NP cultured_VBD from_IN blood_NN (_( R._NP Tomazin_NP and_CC N._NP Hegde_NP ,_, unpublished_JJ data_NNS )_) ._SENT Low_JJ levels_NNS of_IN US2_NP were_VBD expressed_VBN in_IN these_DT cells_NNS ,_, but_CC there_EX was_VBD no_DT obvious_JJ effect_NN on_IN MHC_NP proteins_NNS or_CC antigen_NN presentation_NN (_( Tomazin_NP and_CC Hegde_NP ,_, unpublished_JJ )_) ._SENT Our_PP$ Ad_NN vectors_NNS ,_, e.g._FW ,_, AdtetUS2_NP and_CC AdtetUS11_NP ,_, rely_VBP on_IN the_DT use_NN of_IN the_DT HCMV_NP immediate-early_NP (_( IE_NP )_) promoter_NN that_WDT is_VBZ upregulated_JJ by_IN coinfecting_VBG cells_NNS with_IN a_DT second_JJ Ad_NN vector_NN expressing_VBG a_DT tetracycline_NN transactivator_NN protein_NN ._SENT Rehm_NP et_FW al._FW constructed_VBN AdUS2_NP and_CC AdUS11_NP that_WDT rely_VBP on_IN constitutive_JJ activity_NN of_IN the_DT HCMV_NP IE_NP promoter_NN ._SENT We_PP found_VBD that_IN Ad_NN vectors_NNS utilizing_VBG constitutive_JJ promoters_NNS coupled_VBN to_TO HCMV_NP US2_NP to_TO US11_NP genes_NNS produced_VBD poor_JJ yields_NNS ,_, apparently_RB because_IN these_DT ER-retained_JJ US2_NN to_TO US11_JJ proteins_NNS were_VBD toxic_JJ to_TO 293_CD cells_NNS used_VBN to_TO produce_VB the_DT Ad_NN viruses_NNS (_( reference_NN and_CC data_NNS not_RB shown_VBN )_) ._SENT To_TO compare_VB our_PP$ Ad_NN vectors_NNS with_IN those_DT of_IN Rehm_NP et_FW al._FW ,_, His16_JJ cells_NNS were_VBD infected_VBN with_IN AdtetUS2_NP or_CC AdUS2_NP of_IN Rehm_NP et_FW al._FW ._SENT Both_DT US2-expressing_NP Ad_NN vectors_NNS caused_VBD degradation_NN of_IN class_NN II_NP DRalpha_NP and_CC class_NN I_PP HC_NP in_IN these_DT cells_NNS ._SENT However_RB ,_, AdUS11_NP also_RB reduced_VBD DRalpha_NP in_IN these_DT cells_NNS ,_, whereas_IN our_PP$ AdtetUS11_NN did_VBD not_RB ._SENT Since_IN AdUS11_NP grew_VBD to_TO significantly_RB lower_JJR titers_NNS ,_, larger_JJR amounts_NNS of_IN virus_NN stock_NN were_VBD required_VBN in_IN order_NN to_TO obtain_VB similar_JJ levels_NNS of_IN US11_JJ expression_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Moreover_RB ,_, AdUS11_NP inhibited_VBD expression_NN of_IN an_DT unrelated_JJ cellular_JJ protein_NN ,_, the_DT transferrin_NN receptor_NN ,_, but_CC this_DT was_VBD not_RB the_DT case_NN with_IN AdtetUS11_NP (_( Fig._NN ;_: compare_VB to_TO Ad-betagal_JJ lanes_NNS )_) ._SENT US2_NP delivered_VBD by_IN using_VBG AdUS2_NP also_RB markedly_RB reduced_VBN the_DT stability_NN of_IN class_NN II_NP DRalpha_NP in_IN HeLa-CIITA_NP and_CC 2E12_JJ epithelial_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP concluded_VBD that_IN US2_NP delivered_VBN by_IN both_DT Ad_NN vectors_NNS caused_VBD degradation_NN of_IN both_DT class_NN I_PP and_CC II_NP proteins_NNS in_IN a_DT variety_NN of_IN cells_NNS ,_, and_CC this_DT cannot_MD be_VB the_DT reason_NN for_IN any_DT discrepancies_NNS ._SENT The_DT results_NNS presented_VBD here_RB demonstrate_VB that_IN US2_NP causes_VBZ degradation_NN of_IN MHC_NP class_NN II_NP alpha_NN in_IN several_JJ different_JJ cells_NNS :_: gastric_JJ epithelial_JJ cells_NNS ,_, cervical_JJ carcinoma_NN cells_NNS ,_, and_CC two_CD different_JJ clones_NNS of_IN astroglioma_NN cells_NNS ._SENT The_DT extent_NN of_IN degradation_NN of_IN class_NN II_NP alpha_NN was_VBD similar_JJ or_CC identical_JJ with_IN each_DT cell_NN type_NN at_IN any_DT given_VBN dose_NN of_IN US2_NP ._SENT In_IN cells_NNS expressing_VBG both_DT class_NN I_PP and_CC II_NP proteins_NNS ,_, there_EX was_VBD a_DT 1.5-_CD to_TO 2-fold_JJ preference_NN for_IN class_NN I_PP HC_NP over_IN class_NN II_NP alpha_NN ._SENT The_DT half-life_NN of_IN class_NN II_NP alpha_NN was_VBD reduced_VBN from_IN ~45_NN to_TO 60_CD min_NN down_RB to_TO 2_CD to_TO 5_CD min_NN by_IN expressing_VBG intermediate_JJ levels_NNS of_IN US2_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT Other_JJ homologous_JJ HCMV_NP glycoproteins_NNS ,_, US3_NP and_CC US7_JJ ,_, had_VBD no_DT effect_NN on_IN the_DT stability_NN of_IN MHC_NP proteins_NNS ._SENT Therefore_RB ,_, US2_NP causes_VBZ degradation_NN of_IN class_NN II_CD proteins_NNS in_IN several_JJ relevant_JJ cells_NNS and_CC does_VBZ not_RB show_VB a_DT high_JJ degree_NN of_IN preference_NN for_IN MHC_NP class_VBP I_PP versus_IN class_NN II_NP ._SENT The_DT second_JJ important_JJ set_NN of_IN observations_NNS involved_VBN US2-mediated_JJ degradation_NN of_IN class_NN II_NP DRalpha_NP and_CC DMalpha_NP in_IN cells_NNS expressing_VBG these_DT alpha_NN chains_NNS alone_RB ,_, i.e._FW ,_, without_IN beta_NN and_CC Ii_NP chains_NNS ._SENT There_EX was_VBD no_DT detectable_JJ effect_NN on_IN the_DT DRbeta_NP chain_NN in_IN cells_NNS expressing_VBG DRbeta_NP alone_RB ,_, providing_VBG an_DT important_JJ negative_JJ control_NN for_IN nonspecific_JJ effects_NNS of_IN US2_NP ._SENT These_DT results_NNS have_VBP important_JJ implications_NNS for_IN our_PP$ understanding_NN of_IN how_WRB US2_JJ functions_NNS ._SENT Normally_RB ,_, DRalpha_NP and_CC DRbeta_NP chains_NNS associate_VBP rapidly_RB in_IN the_DT ER_NN and_CC fold_VB extensively_RB to_TO form_VB alphabeta_NN complexes_NNS (_( reviewed_VBN in_IN reference_NN )_) ._SENT Obviously_RB ,_, US2_JJ binding_NN does_VBZ not_RB depend_VB upon_IN protein_NN surfaces_NNS that_WDT evolve_VBP after_IN alphabeta_NN complex_JJ formation_NN ._SENT Instead_RB ,_, US2_NP can_MD bind_VB directly_RB to_TO free_VB alpha_NN chains_NNS ._SENT This_DT highlights_VBZ the_DT rapid_JJ nature_NN of_IN US2-DRalpha_NP interactions_NNS in_IN the_DT ER_NN ._SENT These_DT results_NNS also_RB ruled_VBD out_RP the_DT suggestion_NN that_IN U373_NP cells_NNS transfected_VBN with_IN CIITA_NP express_VBP disproportionate_JJ amounts_NNS of_IN class_NN II_CD proteins_NNS ,_, leading_VBG to_TO induction_NN of_IN unfolded_VBN protein_NN response_NN and_CC ER_NN degradation_NN ,_, because_IN the_DT transiently_RB transfected_JJ HeLa_NP cells_NNS do_VBP not_RB express_VB CIITA_NP ._SENT Cells_NNS that_WDT contained_VBD substantially_RB different_JJ amounts_NNS of_IN class_NN II_NP alpha_NN exhibited_VBD similar_JJ levels_NNS of_IN degradation_NN of_IN alpha_NN chain_NN at_IN any_DT given_VBN concentration_NN of_IN US2_NP ._SENT These_DT observations_NNS support_VBP the_DT hypothesis_NN that_IN US2_NP triggers_VBZ processes_NNS leading_VBG to_TO ER-associated_JJ degradation_NN by_IN recruiting_VBG cellular_JJ proteins_NNS onto_IN MHC_NP proteins_NNS ._SENT The_DT cellular_JJ factors_NNS limiting_VBG in_IN US2-mediated_JJ degradation_NN are_VBP unlikely_JJ to_TO include_VB components_NNS of_IN the_DT Sec61_JJ protein_NN translocon_NN because_IN US2_JJ expression_NN at_IN high_JJ levels_NNS does_VBZ not_RB apparently_RB affect_VB Sec61-mediated_JJ forward_JJ translocation_NN of_IN proteins_NNS into_IN the_DT ER_NN ._SENT The_DT cytoplasmic_JJ tail_NN of_IN US2_NP is_VBZ required_VBN for_IN degradation_NN of_IN MHC_NP proteins_NNS ,_, and_CC our_PP$ group_NN recently_RB showed_VBD that_IN swapping_VBG this_DT domain_NN in_IN place_NN of_IN the_DT US3_NP cytoplasmic_JJ tail_NN produced_VBD a_DT chimera_NN that_WDT could_MD cause_VB degradation_NN of_IN MHC_NP proteins_NNS ._SENT Unlike_IN wild-type_NP US3_NP ,_, US2/US3_NP chimeras_NNS capable_JJ of_IN degrading_JJ MHC_NP proteins_NNS bound_VBN p97_JJ adenosine_NN triphosphatase_NN (_( ATPase_NP )_) ,_, a_DT protein_NN involved_VBN in_IN the_DT extraction_NN of_IN ER_JJ proteins_NNS into_IN the_DT cytoplasm_NN ._SENT Therefore_RB ,_, p97_JJ ATPase_NN may_MD be_VB a_DT candidate_NN cellular_JJ protein_NN that_WDT is_VBZ limiting_VBG in_IN the_DT US2-provoked_JJ retrotranslocation_NN and_CC degradation_NN pathway_NN ,_, but_CC others_NNS are_VBP also_RB likely_JJ to_TO be_VB involved_VBN ._SENT One_CD major_JJ question_NN that_WDT prompted_VBD these_DT studies_NNS was_VBD whether_IN or_CC not_RB US2_NP affects_VBZ class_NN II_NP generally_RB in_IN any_DT cell_NN ,_, in_IN a_DT subset_NN of_IN cells_NNS ,_, or_CC not_RB at_IN all_DT ._SENT Based_VBN on_IN extrapolation_NN of_IN structural_JJ analyses_NNS of_IN the_DT binding_NN of_IN US2_NP to_TO class_VB I_PP HC_NP ,_, Gewurz_NP et_FW al._FW predicted_VBD that_IN US2_NP should_MD bind_VB to_TO the_DT class_NN II_NP beta_JJ chain_NN ,_, rather_RB than_IN the_DT alpha_NN chain_NN ,_, and_CC this_DT group_NN reported_VBD that_IN US2_NP failed_VBD to_TO bind_VB to_TO or_CC cause_VB degradation_NN of_IN class_NN II_CD complexes_NNS in_IN vitro_NN ._SENT However_RB ,_, in_IN these_DT in_IN vitro_NN studies_NNS ,_, US2_NP also_RB failed_VBD to_TO destabilize_VB certain_JJ class_NN I_PP proteins_VBZ that_WDT are_VBP known_VBN to_TO be_VB degraded_VBN in_IN US2-expressing_NP mammalian_JJ cells_NNS ._SENT Thus_RB ,_, these_DT in_IN vitro_NN and_CC structural_JJ studies_NNS failed_VBD to_TO reproduce_VB several_JJ effects_NNS of_IN US2_NP previously_RB observed_VBD in_IN mammalian_JJ cells_NNS ._SENT In_IN the_DT studies_NNS of_IN Rehm_NP et_FW al._FW ,_, relatively_RB large_JJ input_NN doses_NNS (_( 500_CD PFU/cell_NP )_) of_IN an_DT Ad_NN vector_NN expressing_VBG US2_NP were_VBD used_VBN in_IN attempts_NNS to_TO deliver_VB US2_NP into_IN DCs_NP ._SENT There_EX was_VBD little_JJ or_CC no_DT effect_NN on_IN the_DT stability_NN of_IN MHC_NP class_NN I_NP HC_NP ,_, compared_VBN with_IN control_NN cells_NNS ,_, although_IN band_NN intensities_NNS were_VBD not_RB quantified_VBN (_( see_VB Fig._NN in_IN reference_NN )_) ._SENT Given_VBN the_DT well-established_JJ effects_NNS of_IN US2_NP on_IN class_NN I_PP HC_NP in_IN other_JJ cells_NNS ,_, it_PP appears_VBZ that_IN inadequate_JJ amounts_NNS of_IN US2_NP were_VBD delivered_VBN ,_, and_CC any_DT conclusions_NNS about_RB whether_IN or_CC not_RB US2_NP can_MD inhibit_VB class_NN II_NP in_IN DCs_NP or_CC generally_RB in_IN other_JJ cell_NN types_NNS are_VBP not_RB warranted_VBN ._SENT Alternatively_RB ,_, DCs_NP may_MD lack_VB factors_NNS required_VBN by_IN US2_NP to_TO cause_VB class_NN I_PP and_CC II_NP degradation_NN ._SENT We_PP did_VBD not_RB pursue_VB efforts_NNS to_TO test_VB US2_NP 's_POS effects_NNS in_IN DCs_NP here_RB for_IN several_JJ reasons_NNS ._SENT First_RB ,_, DCs_NP and_CC monocyte-macrophages_NNS are_VBP inefficiently_RB infected_VBN by_IN HCMV_NP ,_, especially_RB when_WRB these_DT cells_NNS are_VBP cultured_VBN from_IN blood_NN and_CC infected_VBN by_IN laboratory_NN strains_NNS of_IN HCMV_NP passaged_VBD on_IN fibroblasts_NNS ._SENT Moreover_RB ,_, Ad_NN vectors_NNS often_RB do_VBP not_RB infect_VB DCs_NP well_RB ._SENT For_IN example_NN ,_, the_DT human_JJ immunodeficiency_NN virus_NN nef_NN protein_NN can_MD reduce_VB cell_NN surface_NN expression_NN of_IN MHC_NP class_NN I_PP molecules_NNS in_IN a_DT variety_NN of_IN cells_NNS (_( reviewed_VBN in_IN reference_NN )_) but_CC did_VBD not_RB affect_VB class_VB I_PP when_WRB expressed_VBN by_IN Ad_NN vectors_NNS in_IN DCs_NP ._SENT Our_PP$ preliminary_JJ efforts_NNS to_TO transduce_VB monocyte-macrophages_NNS and_CC DCs_NP cultured_VBD with_IN Ad_NN vectors_NNS lead_VBP to_TO the_DT conclusion_NN that_IN HCMV_NP proteins_NNS could_MD not_RB be_VB delivered_VBN effectively_RB (_( R._NP A._NP Tomazin_NP and_CC N._NP R._NP Hegde_NP ,_, unpublished_JJ results_NNS )_) ._SENT Therefore_RB ,_, we_PP do_VBP not_RB know_VB whether_IN US2_JJ functions_NNS in_IN DCs_NP or_CC macrophages_NNS to_TO inhibit_VB class_NN II_NP antigen_NN presentation_NN ._SENT The_DT question_NN of_IN whether_IN US2_JJ functions_NNS in_IN professional_JJ APCs_NP is_VBZ likely_RB irrelevant_JJ for_IN at_IN least_JJS two_CD reasons_NNS ._SENT First_RB ,_, the_DT high_JJ levels_NNS of_IN MHC_NP proteins_NNS expressed_VBD in_IN APCs_NP ,_, coupled_VBN with_IN low_JJ levels_NNS of_IN viral_JJ gene_NN expression_NN ,_, make_VB it_PP difficult_JJ to_TO imagine_VB that_IN US2_NP ,_, US3_NP ,_, and_CC other_JJ HCMV_NP immune_JJ evasion_NN proteins_NNS could_MD be_VB effective_JJ in_IN these_DT cells_NNS in_IN vivo_RB ._SENT Second_RB ,_, US2_NP and_CC US3_NP are_VBP intracellular_JJ membrane_NN proteins_NNS that_WDT function_VBP only_RB in_IN HCMV-infected_JJ cells_NNS ._SENT In_IN vivo_JJ ,_, only_RB a_DT small_JJ fraction_NN of_IN APCs_NP are_VBP infected_VBN (_( reviewed_VBN in_IN reference_NN )_) ,_, and_CC other_JJ ,_, uninfected_JJ APCs_NNS are_VBP free_JJ to_TO take_VB up_RP HCMV_NP antigens_NNS and_CC effectively_RB prime_JJ or_CC initiate_JJ immune_JJ responses_NNS ._SENT Consistent_JJ with_IN this_DT ,_, there_EX are_VBP robust_JJ and_CC sustained_JJ anti-HCMV_NP CD4+_NP T-cell_NN responses_NNS in_IN humans_NNS (_( reference_NN and_CC references_NNS therein_RB )_) ._SENT Therefore_RB ,_, it_PP is_VBZ highly_RB unlikely_JJ that_IN HCMV_NP benefits_NNS from_IN inhibiting_VBG the_DT class_NN II_NP pathway_NN in_IN APCs_NP ._SENT Rather_RB ,_, we_PP believe_VBP that_IN US2_NP and_CC US3_NP function_VBP to_TO prevent_VB class_NN II-mediated_JJ presentation_NN of_IN endogenous_JJ viral_JJ antigens_NNS in_IN cells_NNS such_JJ as_IN endothelial_JJ ,_, glial_NN ,_, or_CC epithelial_JJ cells_NNS or_CC other_JJ class_NN II-expressing_NN cells_NNS that_WDT are_VBP important_JJ hosts_NNS for_IN HCMV_NP replication_NN in_IN vivo_RB ._SENT Herpesviruses_NNS extensively_RB target_VBP their_PP$ structural_JJ proteins_NNS to_TO endosomal_JJ compartments_NNS (_( reviewed_VBN in_IN reference_NN )_) ,_, where_WRB peptides_NNS destined_VBN to_TO be_VB loaded_VBN onto_IN class_NN II_CD are_VBP generated_VBN (_( reviewed_VBN in_IN references_NNS and_CC )_) ._SENT We_PP have_VBP evidence_NN for_IN highly_RB efficient_JJ loading_NN of_IN peptides_NNS derived_VBN from_IN endogenous_JJ HCMV_NP antigens_NNS ,_, e.g._FW ,_, gB_NN ,_, onto_IN class_NN II_CD proteins_NNS (_( C._NP Dunn_NP ,_, D._NP M._NP Lewinsohn_NP ,_, and_CC D._NP C._NP Johnson_NP ,_, unpublished_JJ results_NNS )_) ._SENT Such_JJ presentation_NN will_MD cause_VB endothelial_JJ or_CC epithelial_JJ cells_NNS to_TO be_VB recognized_VBN by_IN anti-HCMV_NP CD4+_NP T_NN cells_NNS that_WDT can_MD lyse_VB the_DT cells_NNS or_CC produce_VB antiviral_JJ cytokines_NNS ._SENT Therefore_RB ,_, we_PP believe_VBP that_IN the_DT real_JJ function_NN of_IN US2_NP and_CC US3_NP is_VBZ to_TO prevent_VB presentation_NN of_IN endogenous_JJ HCMV_NP antigens_NNS via_IN the_DT class_NN II_NP pathway_NN and_CC recognition_NN of_IN virus-producing_NN cells_NNS ,_, rather_RB than_IN presentation_NN of_IN exogenous_JJ antigens_NNS by_IN professional_JJ APCs_NNS (_( reviewed_VBN in_IN references_NNS and_CC )_) ._SENT The_DT observations_NNS that_WDT US2_NP targets_VBZ several_JJ distinct_JJ MHC_NP proteins_NNS is_VBZ not_RB novel_JJ ._SENT US3_NP affects_VBZ classical_JJ and_CC nonclassical_JJ class_NN I_PP proteins_VBZ ,_, as_RB well_RB as_IN class_NN II_CD proteins_NNS ._SENT HCMV_NP UL16_NP affects_VBZ MIC-B_NP ,_, UL16-binding_NP protein-1_NN (_( ULBP-1_NP )_) ,_, and_CC ULBP-2_NP ._SENT Human_JJ immunodeficiency_NN virus_NN nef_NN targets_VBZ CD4_NN and_CC class_NN I_PP molecules_NNS for_IN demise_NN in_IN lysosomes_NNS and_CC alters_VBZ sorting_VBG and_CC peptide_NN loading_NN of_IN class_NN II_CD proteins_NNS ._SENT The_DT Kaposi_NP 's_POS sarcoma_NN herpesvirus_NN K3_NP and_CC K5_NP proteins_NNS target_VBP MHC_NP class_NN I_PP proteins_VBZ HLA-A_NP ,_, -B_NN ,_, -C_NN ,_, and_CC -E_NNS for_IN internalization_NN from_IN the_DT cell_NN surface_NN followed_VBN by_IN degradation_NN ,_, and_CC K5_NP also_RB downregulates_VBZ B7-2_NP and_CC ICAM-1_NP ._SENT Therefore_RB ,_, many_JJ viral_JJ immunomodulatory_NN proteins_NNS have_VBP apparently_RB evolved_VBN to_TO affect_VB multiple_JJ molecules_NNS that_WDT exhibit_VBP only_RB limited_JJ homology_NN but_CC with_IN shared_VBN structural_JJ features_NNS ._SENT Expression_NN of_IN class_NN II_CD proteins_NNS by_IN various_JJ cell_NN lines_NNS ._SENT Expression_NN of_IN class_NN II_CD proteins_NNS by_IN various_JJ cell_NN lines_NNS ._SENT His16_NN ,_, HeLa-CIITA_NP ,_, and_CC 2E12_JJ cells_NNS were_VBD labeled_VBN in_IN suspension_NN for_IN 2_CD ,_, 4_CD ,_, or_CC 8_CD min_NN with_IN [_SYM 35S]methionine-cysteine_JJ ,_, and_CC the_DT label_NN was_VBD chased_VBN for_IN 0_CD or_CC 20_CD min_NN ._SENT NP-40-DOC_NP cell_NN extracts_VBZ derived_VBN from_IN 6_CD x_NN 106_CD (_( His16_NN ,_, 2E12_JJ )_) or_CC 15_CD x_NN 106_CD (_( HeLa-CIITA_NP )_) cells_NNS were_VBD mixed_VBN with_IN anti-DRalpha_NP MAb_NP DA6.147_NP ,_, and_CC MHC_NP class_NN II_NP complexes_NNS immunoprecipitated_VBD ._SENT US2_NP causes_VBZ loss_NN of_IN class_NN I_PP and_CC II_NP proteins_NNS ._SENT US2_NP causes_VBZ loss_NN of_IN class_NN I_PP and_CC II_NP proteins_NNS ._SENT (_( A_NP )_) His16_NN ,_, HeLa-CIITA_NP ,_, or_CC 2E12_JJ cells_NNS were_VBD left_VBN uninfected_JJ (_( 0_CD PFU/cell_NP )_) or_CC were_VBD infected_VBN with_IN AdtetUS2_NP and_CC Adtet-trans_NP using_VBG 3_CD and_CC 0.6_CD ,_, 10_CD and_CC 2_CD ,_, 30_CD and_CC 6_CD ,_, 100_CD and_CC 20_CD ,_, or_CC 300_CD and_CC 60_CD PFU/cell_NNS ,_, respectively_RB ,_, for_IN 18_CD h._JJ Infected_JJ cells_NNS were_VBD labeled_VBN with_IN [_SYM 35S]methionine-cysteine_JJ for_IN 3_CD h_NN ,_, and_CC cell_NN extracts_VBZ were_VBD made_VBN using_VBG NP-40-DOC_NP lysis_NN buffer_NN ._SENT Class_NP II_NP complexes_NNS were_VBD immunoprecipitated_VBN from_IN 6_CD x_NN 106_CD (_( His16_NN ,_, 2E12_JJ )_) or_CC 15_CD x_NN 106_CD (_( HeLa-CIITA_NP )_) cells_NNS using_VBG MAb_NP DA6.147_NP ._SENT (_( B_NP )_) His16_NN (_( 6_CD x_SYM 106_CD )_) and_CC HeLa-CIITA_NP (_( 15_CD x_SYM 106_CD )_) cells_NNS were_VBD left_VBN uninfected_JJ (_( 0_CD PFU/cell_NP )_) or_CC were_VBD infected_VBN with_IN AdtetUS2_NP ,_, AdtetUS3_NP ,_, or_CC AdtetUS7_JJ ,_, in_IN each_DT case_NN with_IN Adtet-trans_NNS using_VBG 30_CD and_CC 6_CD PFU/cell_NP or_CC 150_CD and_CC 30_CD PFU/cell_NNS ,_, respectively_RB ,_, for_IN 18_CD h._NN 